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ABSTRACT
The purpose of this study was to define the maximal tolerated dose (MTD), extramedullary toxicities, and
pharmacokinetics of docetaxel combined with high-dose melphalan and carboplatin with autologous hemato-
poietic progenitor cell support. Fifty-nine patients with advanced refractory malignancy (32 breast cancer, 10
non-Hodgkin lymphoma, 6 germ cell tumors, 4 Hodgkin disease, 4 ovarian cancer, 2 sarcoma, and 1 unknown
primary adenocarcinoma) with a median of 3 prior chemotherapy regimens and a median of 3 organs involved
were enrolled. Treatment included docetaxel (150-550 mg/m2 infused over 2 hours on day 6), melphalan
(150-165 mg/m2 infused over 15 minutes from day 5 to 3), and carboplatin (1000-1300 mg/m2 as a 72-hour
continuous infusion from day 5). Five patients died from direct regimen-related organ toxicity (2 capillary
leak syndrome, 2 enterocolitis, and 1 hepatic toxicity), and 1 additional patient died from pulmonary aspergil-
losis. The docetaxel MTD was defined as 400 mg/m2, combined with melphalan (150 mg/m2) and carboplatin
(1000 mg/m2). The MTD cohort was expanded to enroll a total of 26 patients, 1 of whom died from toxic
enterocolitis. The remaining 25 patients presented the following extramedullary toxicity profile, which was
manageable and largely reversible: stomatitis, myoarthralgias, peripheral neuropathy, gastrointestinal and
cutaneous toxicities, and syndrome of inappropriate antidiuretic hormone secretion. Docetaxel exhibited linear
pharmacokinetics in the dose range tested (150-550 mg/m2). Pharmacodynamic correlations were noted
between the docetaxel area under the curve and peripheral neuropathy or stomatitis. The response rate among
38 patients with measurable disease was 95%, with 47% complete responses. At a median follow-up of 26
months (range, 7-72 months), the 3-year event-free survival and overall survival were 26% and 36%, respec-
tively. In conclusion, a 4-fold dose escalation of docetaxel, combined with melphalan and carboplatin, is feasible
with autologous hematopoietic progenitor cell support. The notable activity of this regimen in treatment-
refractory patients warrants its further evaluation.
© 2005 American Society for Blood and Marrow Transplantation
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tNTRODUCTION
Tumor relapse constitutes the major cause of
reatment failure after high-dose chemotherapy (HDC)
nd autologous hematopoietic progenitor cell (AHPC)
ransplantation. Most HDC regimens are based on p
B & M Tlkylating drugs, which show a linear concentration-
esponse relationship in vitro but present an intrinsic
ntitumor activity for the disease in question that is
ften modest. Development of new HDC combina-
ions that include more active drugs may improve
atient outcome [1].
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2With the goal of increasing the activity of HDC
or solid tumors, regimens including paclitaxel were
eveloped in the past decade [2-5]. The semisynthetic
axane docetaxel (Taxotere; Aventis, Bridgewater, NJ)
as preclinical and clinical features that are advanta-
eous for this purpose. Docetaxel exhibits greater po-
ency than paclitaxel in multiple preclinical models
6-8]. Besides microtubule dynamics, its major target,
ocetaxel also interferes with apoptotic, angiogenesis,
nd gene expression processes [9]. In several random-
zed studies, docetaxel has been shown to be probably
he most active agent for breast cancer [10-14]. There
s also evidence of its signiﬁcant activity in other solid
umors [15-19].
Preclinical data in tumor cell cultures, murine
umor models, and human tumor xenografts give ev-
dence of the dose-dependent and schedule-indepen-
ent nature of the antitumor effect of docetaxel, in
ontrast to paclitaxel [20-22]. Clinical trials testing
ocetaxel at a range of conventional doses have shown
nferior response rates at reduced dosages [23,24]. A
andomized trial has shown signiﬁcantly greater com-
lete and overall responses for 100 mg/m2 compared
ith 75 or 60 mg/m2 [25].
The docetaxel toxicity spectrum is largely domi-
ated by neutropenia [26,27]. Hypersensitivity reac-
ions are uncommon with dexamethasone premedica-
ion. Capillary leak syndrome, although decreased
ith the use of dexamethasone, still occurs at high
umulative doses. Asthenia is common but is severe in
minority of patients. Other nonhematologic side
ffects, such as peripheral neuropathy, arthralgia and
yalgia, skin rash, hand-foot syndrome, or nail disor-
ers, are mild in most patients. Mucositis was seen in
arly trials of continuous infusions of docetaxel but is
ncommon in shorter administrations. Altogether, the
roﬁle of docetaxel suggests that it may be an appro-
riate drug for attempting AHPC-supported dose es-
alations.
An important consideration in developing high-
ose regimens consists of the lack of overlapping
xtramedullary toxicities between agents [1]. In this
egard, both melphalan and carboplatin seem suit-
ble candidates for combination with docetaxel.
arboplatin is the preferred platinum for HDC on
he basis of its lack of extramedullary toxicities at
tandard doses [28]. Melphalan presents a broad
ctivity spectrum, a steep dose-response effect, a
aucity of extramedullary toxicities, and linear and
redictable pharmacokinetics (PK), all of which
ake it widely used in HDC [29]. Their nonhema-
ologic toxicities at high doses, nephrotoxicity/oto-
oxicity/peripheral neuropathy [30], and mucositis
29], respectively, appear largely nonoverlapping
ith those of standard-dose docetaxel. Further,
here is evidence of synergy between docetaxel and
latinum compounds or alkylating agents [31-33]. l
98inally, carboplatin and melphalan, which undergo
lomerular ﬁltration and plasma hydrolysis, respec-
ively [1], do not share PK pathways with docetaxel,
hich is metabolized in the cytochrome P450 3A4
icrosomal system [34]. This suggests that clini-
ally relevant PK interactions between these agents
re unlikely. We hypothesized that a major dose
scalation of docetaxel is feasible with AHPC sup-
ort. We report a phase I and PK trial of docetaxel
ombined with high-dose melphalan and carbopla-
in.
ATIENTS AND METHODS
atient Population
This trial was conducted at the University of
olorado under a Food and Drug Administration In-
estigational New Drug application. The study pro-
ocol was approved by the Institutional Review Board
nd Cancer Center Protocol Review Committee. An
xternal Data Safety Monitoring Board reviewed the
ata every 6 months. All patients gave written in-
ormed consent before study entry.
Eligibility was restricted to patients with advanced
efractory tumors. Breast cancer patients met 1 of
he following criteria: tumor progression while receiv-
ng chemotherapy, no response after 2 lines of che-
otherapy for metastatic disease, unresponsive liver
etastases, asymptomatic central nervous system
CNS) disease, relapse within an irradiated ﬁeld, or
rior HDC. Patients with ovarian carcinoma had
arge-volume disease after second-line chemotherapy,
3 prior chemotherapy regimens, chemorefractory
isease, or unresponsive parenchymal liver disease.
atients with non-Hodgkin lymphoma (NHL),
odgkin disease (HD), or germ cell tumors (GCTs)
ere eligible if they had experienced no response or
rogression after second-line chemotherapy. Che-
orefractory patients with other diagnoses were eli-
ible.
General physical criteria included full recovery
rom the acute toxic effects of prior therapy, a perfor-
ance status of 0 or 1, and acceptable end-organ
erformance: creatinine clearance 60 mL/min, left
entricular ejection fraction 45%, diffusion capacity
f carbon monoxide and forced expiratory volume in 1
econd 60% of predicted, liver function tests (aspar-
ate aminotransferase, alanine aminotransferase, and
ilirubin) 2 times their upper normal limits, and
cceptable bone marrow function, with a white blood
ell count of 3000/mm3, absolute neutrophil count
1000/mm3, and platelet count 100 000/mm3. Pre-
ious cumulative doxorubicin exposure was limited to
50 mg/m2. Prior treatment with docetaxel, melpha-
an, or platinum compounds was allowed.
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Dose Escalation of Docetaxel with Stem Cell Support
Breatment
Upon admission on day 7, dexamethasone was
nitiated at 8 mg orally (PO) or intravenously (IV)
wice daily (BID) for 8 doses (Table 1). Docetaxel was
nfused over 2 hours on day 6. Melphalan was in-
used over 15 minutes from day 5 to day 3 at
0 mg/m2/d (except for the 4 patients in cohort 7
reated at 55 mg/m2/d). Carboplatin was administered
s a 72-hour continuous infusion starting on day5 at
33 mg/m2/d (except for the 2 patients in cohort 8
ho received 433 mg/m2/d). Hydration with 0.9%
aline was administered at 100 mL/h from day 7 in
he afternoon to day 6 in the afternoon and at 250
L/m2/h thereafter, ﬁnishing on day 2, 4 hours
fter the completion of the carboplatin infusion. An-
iemetics included perchlorperazine (5 mg PO/IV 3
imes daily [TID] on day 6) and ondansetron (16 mg
V once daily [QD] from day 5 to day 0).
Supportive care was uniform. Levoﬂoxacin (500 mg
V/PO QD from day 1 until neutrophil engraft-
ent), acyclovir (800 mg PO or 5 mg/kg IV BID from
ay 1 until day 45), and ﬂuconazole (400 mg
V/PO QD from day1 until day45) were used for
nfection prophylaxis. Prevention and treatment of
tomatitis included oral cryotherapy with ice chips
uring the melphalan infusions [35,36] and glutamine
outhwashes from day 1 [37-39]. Patients with
ymptomatic hyponatremia or serum sodium 125
Eq/L, meeting syndrome of inappropriate antidi-
retic hormone secretion (SIADH) criteria, were
reated with furosemide-induced diuresis and saline
olume replacement.
AHPCs were infused on day 0. Empiric treatment
f febrile neutropenia included cefepime (2 g IV TID)
nd vancomycin (1 g IV BID), and amphotericin B
eoxycholate (0.6 mg/kg IV QD; 1998-2000) or lipid
omplex (3 mg/kg IV QD; since 2000) if there was no
efervescence after 96 hours. Myoarthralgias and neu-
opathic pain were treated with gabapentin, starting at
00 mg PO at bedtime and escalating rapidly to
00 mg PO TID. Pyridoxine 50 mg PO TID was
dministered for hand-foot syndrome [40].
able 1. Treatment Schema at the Study MTD
Variable 7 6
ocetaxel 400 mg/m2, 2-h IV infusion 
elphalan 50 mg/m2/d IV
arboplatin 1000 mg/m2, 72-h CI IV
V hydration 4.... ......
examethasone 8 mg IV/PO BID  
HPCV indicates intravenous; CI, continuous infusion; AHPC, autologous hem
B & M Tose Escalation
Toxicity scoring followed the National Cancer
nstitute Common Toxicity Criteria, version 2.0 [41].
ocetaxel was escalated by 100 mg/m2 per cohort,
tarting at 150 mg/m2, with ﬁxed doses of melphalan
nd carboplatin. Early stopping rules for excessive
oxicity mandated discontinuation of the trial if 5 of
he ﬁrst 10 patients experienced regimen-related mor-
ality. At least 3 patients were enrolled in each dose
evel. If none experienced greater than grade 3 ex-
ramedullary toxicity, the dosage was to be escalated.
f 1 patient experienced unacceptable toxicity, then a
ourth patient would be enrolled in that cohort. If 2
atients experienced greater than grade 3 toxicity,
hen that dose was considered unacceptably toxic. The
0% conﬁdence limits, using the exact binomial dis-
ribution, for excessive toxicity at any level were 0.13
o 0.87 for 1 in 3 patients and 0.06 to 0.58 for 1 in 4
atients. Upon reaching a dose too toxic, docetaxel
ould be de-escalated 1 step. The maximal tolerated
ose (MTD) was deﬁned as the highest dose causing
1 case of grade 4 or 5 toxicity in 4 patients. Sub-
equently, melphalan and carboplatin would be esca-
ated in 15 and 300 mg/m2 increments, respectively.
After MTD was reached, an amendment to the
rotocol was approved that allowed the expansion of
he MTD cohort with enrollment of 20 additional
atients, with the goal of better deﬁning the toxicity
roﬁle of the new regimen. Objective responses were
valuated according to current guidelines for solid
umors [42] and lymphomas [43].
valuation of Peripheral Neuropathy
Sequential neurologic evaluations that quantiﬁed
bnormalities in sensory symptoms, pin sensibility,
osition sensation, toe/ﬁnger strength, and deep ten-
on reﬂexes used the clinical parameters of a previ-
usly described peripheral neuropathy score [44].
linical examinations were performed by the same
bserver before transplantation, at discharge (2-3
eeks after transplantation), and 1 month after dis-
harge.
Day
5 4 3 2 1 0
  
.... ...... ....3
...... ...... ...... ....3
 
4atologic progenitor cells.
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3ocetaxel PK Analyses
Samples were drawn from a site remote from the
nfusion catheter before infusion, mid infusion, at the
nd of infusion, and at 2, 4, 8, 12, 18, and 22 hours
fter the end of the infusion. Ten milliliters of blood
as collected in a heparinized tube, placed on ice, and
apidly centrifuged at 2000g for 10 minutes at 0°C to
°C. Five milliliters of plasma was extracted by vor-
exing with an equal volume of high-performance liq-
id chromatography (HPLC)–grade ethyl acetate
ontaining paclitaxel 1 mol/L at 25 L/mL as an
nternal standard (IS). All samples were stored at 0°C
o 5°C and were protected from light. For analysis, the
xtraction solvent/IS layer was aspirated and dried
nder a nitrogen stream. The residue was reconsti-
uted with 300 L of HPLC-grade acetonitrile and
ransferred to limited-volume HPLC vials. Standard
amples were prepared with reagent-grade docetaxel
dded to blank pooled whole blood. Samples were
nalyzed with a Waters HPLC system (Waters,
ilford, MA) equipped with two 512 pumps, a Wisp
12 autosampler (Waters), and a 490 multichannel/
ultiwavelength UV detector and radial compression
odule with a Nova-Pak C-18 4-m column car-
ridge and precolumn (Waters). Samples were eluted
ver 15 minutes with an acetonitrile/water gradient
rom 20% to 100% acetonitrile at constant ﬂow of
mL/min. The efﬂuent was analyzed at detection
avelengths of 235 and 220 nm.
Sample peak areas were compared with IS peak
reas, and the resulting ratio was compared with a
lasma calibration curve derived from 7 samples with
nown concentrations (0.01-20 g/mL). Intrarun pre-
ision was evaluated through analysis of standard rep-
icates of daily analyses. The intrarun and interrun
recision coefﬁcient variation of this assay was10%.
hree-compartment and noncompartmental analyses
sed WinNonlin 3.0 (Pharsight Corporation, Mountain
iew, CA).
tatistical Analyses
The event-free survival (EFS) was estimated from
he ﬁrst HDC day until tumor progression, relapse, or
eath from any cause. Overall survival (OS) was esti-
ated from HDC start until death. Univariate linear
egression analysis was used to assess the PK/pharma-
odynamic correlations of docetaxel.
ESULTS
atient Enrollment
Between 1998 and 2003, 59 patients were enrolled
Table 2). They were heavily pretreated (a median of
prior regimens) and had extensive tumor involve-
ent (median of 3 organs). Their diagnoses included p
00reast cancer (n  32), NHL (n  10), GCT (n  6),
D (n  4), ovarian cancer (n  4), and 1 each of
habdomyosarcoma, Ewing sarcoma, and unknown
rimary adenocarcinoma. Dose escalation and de-es-
alation proceeded as shown in Table 3.
DC Toxicities
Treatment-Related Deaths. Five patients died from
egimen-related toxicity (Table 3): capillary-leak syn-
rome (n  2), enterocolitis (n  2), and hepatocel-
ular necrosis (n 1). Four received docetaxel at450
g/m2, and 1 received the MTD. One additional
atient, treated at 450 mg/m2, died from invasive
ulmonary aspergillosis 3 months after posttransplan-
ation discharge.
The picture of capillary-leak syndrome consisted
f rapid acute respiratory insufﬁciency with pulmo-
ary edema, hypotension, and generalized anasarca,
egative blood cultures, and normal cardiac function.
he patient who experienced fatal acute hepatocellu-
ar necrosis had extensive breast cancer metastases to
he liver; this caused increased liver function tests,
lbeit within the protocol eligibility criteria, and he-
atic cirrhosis that was not noticed until after trans-
lantation. The patient who died from enterocolitis
fter receiving the MTD had previously received the
ighest cumulative dose of docetaxel of the study
able 2. Patient Demographics (n  59)
Variable Data
ge, y, median (range) 46 (10-66)
ex
Female 42
Male 17
iagnosis
Breast cancer 32
Non-Hodgkin lymphoma 10
Germ cell tumor 6
Hodgkin disease 4
Ovarian cancer 4
Unknown primary adenocarcinoma 1
Ewing sarcoma 1
Rhabdomyosarcoma 1
o. prior chemotherapy regimens,
median (range) 3 (1-6)
No. patients with prior docetaxel 16
Median cumulative dose (range) 300 mg/m2 (100-715)
o. organs involved, median (range) 3 (1-7)
Peripheral lymph nodes 26
Lungs 23
Bone 21
Liver 20
Retroperitoneum 18
Mediastinum 16
Bone marrow 8
Pleura 8
Central nervous system 7
Chest wall 8
Stomach 2
Adrenals 1opulation (715 mg/m2).
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Dose Escalation of Docetaxel with Stem Cell Support
B B &Doses of docetaxel 450 mg/m2 and escalation of
elphalan and carboplatin above their initial doses
ere deemed unsafe. The ﬁnal MTD was deﬁned at
ocetaxel 400 mg/m2, melphalan 150 mg/m2, and car-
oplatin 1000 mg/m2. To better deﬁne the toxicity
roﬁle of the new regimen, the MTD cohort was
xpanded to enroll a total of 26 patients. These pa-
ients treated at the MTD presented the following
ide-effect proﬁle (Table 3).
Mucositis. Stomatitis occurred early in the second
eek, peaking at a median of day 2, with a median
uration of 7 days. Eight and 12 patients experienced
rade 3 and grade 2 lesions, respectively.
Myoarthralgias. Early (median onset on day 3)
yoarthralgias were frequent, responded promptly to
nalgesics, and lasted a median of 6 days. They were
onsidered grade 3 in 1 case and grade 2 in 17 cases.
Peripheral Neuropathy. Most patients who received
ocetaxel 400 mg/m2 experienced sensory and mo-
or neuropathy starting on median day 2. It was
rade 3 in 9 patients and grade 2 in 6 patients at the
TD. Signiﬁcant recovery occurred rapidly in the
rst few weeks after discharge (Figure 1). At 3-month
valuation, clinical improvement of neuropathy was
oted in all cases. It was downgraded to grade 2 (n 
0) and grade 1 (n  9) in 19 patients who had
xperienced acute grade 3 neuropathy, and it was
cored as grade 1 (n  13) and grade 0 (n  2) in 15
atients who had previously experienced an acute case
f grade 2. Neuropathic pain was scored as grade 3 in
patients and as grade 2 in 12 patients. It responded
o gabapentin and eventually resolved in all cases.
Constipation/Ileus. Constipation/ileus was seen at
ll dose levels and was grade 3 in all cases. It pre-
ented in the ﬁrst week after transplantation and re-
olved in1 week. At the MTD, there were 4 cases of
rade 3 ileus, which resolved rapidly with neostigmine
45]. There were 4 cases of grade 2 constipation.
Diarrhea/Colitis. There was 1 fatal case of entero-
olitis at the MTD. Additionally, there were 3 cases of
rade 3 diarrhea (2 with incontinence) and 1 of grade
diarrhea, which presented in the ﬁrst week after
ransplantation and resolved within 10 days. No sen-
orial deﬁcits were noted on perirectal examinations.
igure 1. Clinical neuropathy score before and at different times
after HDC in patients treated at the MTD (n  26).T
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3Skin. An erythematous rash was common at doses
400 mg/m2. It typically developed in the ﬁrst week
fter transplantation, was asymptomatic in most cases,
nd resolved within 1 to 2 weeks. It was present in 25
f 26 patients treated at the MTD: grade 2 in 11
atients and grade 3 in 4 patients. In addition to
outine skin care and topical moisturizing petrolatum
Aquaphor; Beiersdorf, Wilton, CT), 2 patients re-
uired systemic analgesics for 1 week.
Additionally, 7 patients treated at the MTD devel-
ped hand-foot syndrome, with a similar time course. It
as grade 3 in 1 patient and grade 2 in 6 patients. One
atient treated at the MTD developed asymptomatic
acial cystic acne at 3 months after transplantation. It
esolved spontaneously by the 6-month visit.
Nails. Thirteen patients treated at the MTD de-
eloped grade 2 onycholysis. In all cases, nails grew
ack within 2 to 3 months.
Syndrome of Inappropriate Antidiuretic Hormone
ecretion. A total of 15 patients treated at doses
400 mg/m2 developed transient SIADH, with a me-
ian lowest serum sodium of 123 mEq/L (range, 114-
27 mEq/L) appearing on a median of day 1 (range,
ay 2 to day 1) and resolving within 48 hours. It
as asymptomatic in all patients but 1, who com-
lained of a headache for several hours.
Hepatic. Mild early acute hepatitis, asymptomatic
nd rapidly reversible, was noticed throughout the
tudy. The median onset was day3; it peaked on day
1 and resolved within 1 week.
Effects on Other Vital Organs. No cardiac or cere-
ral toxicities were observed in the entire study. Pre-
nd post-HDC left ventricular ejection fractions were
1% (range, 45%-75%) and 59% (range, 51%-74%),
espectively (P  .15). There were no cases of pulmo-
ary or renal toxicity at the MTD. The pretransplan-
ation and posttransplantation diffusion capacity of
arbon monoxide did not vary signiﬁcantly: 78%
range, 61%-115%) versus 72% (range, 59%-115%),
espectively (P  .10).
oxicity in Patients Previously Exposed
o Docetaxel
Six patients enrolled at the MTD had received
rior docetaxel with a median cumulative dose of
able 4. Docetaxel AUC and Cmax at Different Dose Levels
Dose (mg/m2)
AUC g · mL1 · min
Median Me
150 190 190
250 330 310
350 520 590
400 700 1080
450 1050 970
500 1210 1150
550 1190 1160UC indicates area under the curve; Cmax, maximal drug concentration.
0240 mg/m2 (range, 215-715 mg/m2). The patient with
he highest prior docetaxel exposure (715 mg/m2) died
rom enterocolitis. The other 5 patients (prior expo-
ure of 350 mg/m2) did not seem to experience
ncreased toxicity compared with the other patients of
his cohort. Ten additional patients previously treated
ith docetaxel (median, 300 mg/m2; range, 150-400
g/m2) were treated in other cohorts (docetaxel 350-
50 mg/m2) without grade 4 or 5 toxicities.
ematologic Recovery
Neutrophils decreased to 100/mm3 on a median
f day 0 (range, day 2 to day 1), engrafting on a
edian of day 9 (range, day 6 to day 25). Plate-
ets decreased to20 000/mm3 on a median of day3
range, day 1 to day 5), engrafting on day 15
range, day 9 to day 49). There were no cases of
ate graft failure.
K and Pharmacodynamic Analyses
PK studies of docetaxel were performed in 51
atients (Table 4). The docetaxel area under the curve
AUC; r  0.66; P  .0001; Figure 2) and maximal
rug concentration (Cmax) (r  0.48; P  .0003) in-
reased linearly with dose. In contrast, its terminal
alf-life did not change signiﬁcantly with dose (r 
.8; P  .70). The average (standard deviation) values
f half-life, volume of distribution, and clearance were
.5 hours (1.4 hours), 512 L/m2 (770 L/m2), and 60
/m2/h (56 L/m2/h), respectively.
Signiﬁcant pharmacodynamic correlations were
bserved between the docetaxel AUC and peripheral
europathy (r  0.6; P  .0001; Figure 3A), and
tomatitis (r  0.4; P  .01; Figure 3B), but not with
ny of the other toxicities. Correlations between gas-
rointestinal toxicity (enteritis, constipation, or both)
nd AUC were marginally signiﬁcant (P  .05) and
eak (r  0.2). The maximal drug concentration or
erminal half-life did not correlate with any toxic end
oints (data not shown).
lanned Post-HDC Treatment
Three patients with GCT received a second HDC
ycle (carboplatin/etoposide) administered within 3
Cmax g · mL
1
ge) Median Mean (range)
10) 1.1 1.1 (0.9-1.3)
40) 1.9 2 (1.8-2.1)
40) 2.9 3.3 (2.1-5.1)
570) 3 3.7 (0.6-9.7)
590) 5.2 5.4 (2.2-10.7)
520) 4.3 4.6 (3.1-6.4)
710) 4.8 5 (3.3-6.5)1
an (ran
(170-2
(270-3
(470-8
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(710-1
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Dose Escalation of Docetaxel with Stem Cell Support
Bonths. Four patients with persistent or progressive
reast cancer and 1 patient with HD in complete
emission (CR) received a nonmyeloablative trans-
lant from an HLA-matched sibling 2 to 6 months
fter HDC. Two of those breast cancer patients died
rom progressive disease, 1 died as a result of compli-
ations associated with graft-versus-host disease
GVHD), and the fourth is experiencing an ongoing
esponse associated with GVHD. The HD patient
emains in CR, with full donor chimerism and no
VHD, 6 months after the nonmyeloablative proce-
ure.
Posttransplantation radiotherapy was adminis-
ered to 12 breast cancer patients to bone (n  7),
hest wall (n  3), and CNS (n  2). Two patients
ith sarcoma received radiotherapy to osseous metas-
ases, and 1 patient with NHL received chest wall
adiation.
ctivity and Outcome
Thirty-six (94.7%) of 38 patients with measurable
isease responded, with 18 (47%) CRs, 4 of which
ere pathologically documented. The median re-
ponse duration was 6 months (range, 3 to 70
onths). CRs were seen in patients with breast cancer
8/16), NHL (2/5), HD (2/4), ovarian cancer (2/3),
CT (3/6), and sarcoma (1/2). Eight patients without
response to prior standard-dose docetaxel (progres-
ive disease in 7 and stable disease in 1) responded, and
here were 3 CRs.
At the current median follow-up of 26 months
range, 7-72 months), 23 patients are alive, and 16
ave no evidence of disease (8 breast cancer, 3 NHL,
GCT, 1 sarcoma, and 1 ovarian cancer). One patient
ied from a second primary tumor (non–small-cell
ung cancer) 21 months after HDC while still in CR
rom her original NHL. The 7 patients with brain
etastases died (all with breast cancer): 6 from tumor
rogression, 1 from HDC-related toxicity, and 1 from
VHD after a subsequent nonmyeloablative alloge-
igure 2. Linear correlation between docetaxel AUC and dose (r 
.66; P  .001).eic transplantation. Among all enrolled patients, the B
B & M T-year EFS and OS probabilities are 26% and 36%,
espectively, with median EFS and OS times of 7 and
6 months, respectively (Figure 4).
ISCUSSION
This phase I study shows the feasibility of a major
-fold AHPC-supported dose escalation of docetaxel
ombined with high doses of melphalan and carbopla-
in. Docetaxel dose-limiting toxicities above the MTD
ere capillary leak syndrome, enterocolitis, and he-
atic toxicity. The MTD of docetaxel was deﬁned at
00 mg/m2. No signiﬁcant hepatic, cardiac, pulmo-
ary, renal, or CNS toxicities were observed among
6 patients enrolled at the MTD, although 1 patient
ith heavy prior docetaxel exposure died from entero-
olitis. In the remaining 25 patients, who received
ocetaxel 400 mg/m2, we observed a manageable pro-
le of stomatitis, peripheral neuropathy, rash, hand-
oot syndrome, diarrhea, or constipation, all of which
eaked early in the ﬁrst posttransplantation week and
mproved rapidly. Similar to weekly docetaxel [46,47],
ome patients experienced onycholysis. In contrast,
asolacrimal duct stenosis, also reported with weekly
dministration [48], was not observed. Capillary leak
yndrome, which limited chronic docetaxel treatment
n early studies [49], was dose limiting in our study but
as not seen in the cohort treated at the MTD. Mild
eripheral neuropathy and asthenia were the only
igure 3. Pharmacodynamic correlations of docetaxel. A, Correla-
ion between peripheral neuropathy and AUC (r  0.6; P  .0001).
, Correlation between stomatitis and AUC (r  0.4; P  .01).
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3osttransplantation residual side effects, and both
radually improved over several weeks.
This toxic proﬁle has been previously described
ith standard-dose docetaxel [26,27,50]. In contrast,
IADH, seen in one third of our patients, was only
necdotally reported after conventional docetaxel [51].
t was usually asymptomatic in our patients, was easily
anageable, and resolved rapidly. SIADH is possible
fter high-dose melphalan [52], but it is more uncom-
on than in our study. Therefore, we attribute this
ide effect to high-dose docetaxel or a combined effect
rom both drugs.
Fifteen of the 16 patients previously treated with
ocetaxel did not experience increased toxicity, with
he exception of 1 toxic fatality in a heavily pre-
xposed patient. It is interesting to note that re-
ponses, including CRs, were seen in patients who had
reviously not responded to docetaxel. This limited
xperience suggests that future studies of high-dose
ocetaxel should not exclude patients with prior do-
etaxel treatment as long as previous exposure is lim-
ted to 350 to 400 mg/m2.
DNA-targeting drugs have traditionally consti-
uted the backbone of HDC regimens. Docetaxel has
hown synergy with these drugs [33]. There is increas-
ng interest in combinations of docetaxel and platinum
ompounds [53-55] or alkylating agents [56,57]. Al-
hough evaluation of activity was not a primary end
oint of this study, we observed a high level of activity
n our population of patients with heavily pretreated
efractory tumors. Responses were seen in a broad
rray of tumors, including some in which standard-
ose docetaxel has shown limited activity, such as
HL [58,59], or those with virtually no previous
linical data, such as HD or GCT. It is possible that
elphalan and carboplatin might have had a substan-
ial contribution in those tumors in which docetaxel
as modest or unknown intrinsic activity.
We observed a linear disposition of docetaxel, and
his suggests nonsaturability of its metabolic pathways.
igure 4. Kaplan-Meier EFS and OS curves (all patients; n  59).here is evidence of linearity of its PK within the
04onventional dose range (100 mg/m2) [33] or above
ts standard doses at 100 to 175 mg/m2 [60]. Our
esults show that the PK of docetaxel remain linear at
he highest end of its dosing spectrum. The consistent
inear disposition of docetaxel contrasts with the non-
inear PK proﬁle of paclitaxel at conventional [61] or
igh [5,62] doses.
Other authors have tested dose escalation of do-
etaxel above its standard dose. Phase I studies of
ingle-agent docetaxel administered in 1 to 3 cycles
ith granulocyte colony-stimulating factor support
etermined its MTD at 160 to 185 mg/m2 per cycle
60,63,64]. Dose escalation of docetaxel in multiple
HPC-supported cycles, combined with high-dose
yclophosphamide and thiotepa, was not feasible at
100 mg/m2 [65]. The side-effect proﬁle of repetitive
ycles of escalated docetaxel included dermatitis, mu-
ositis, diarrhea, and neuromuscular symptoms (simi-
ar to our observations). Although these side effects
esolved rapidly in our study and seemed tolerable for
1-time treatment, they may constitute a major ob-
tacle for full administration of a multicycle high-dose
rogram.
In view of its high activity in our treatment-refrac-
ory population and its reversible toxicity proﬁle, this
egimen is worthy of future testing in patients with
ensitive disease. Three patients tolerated without dif-
culty a planned second HDC cycle of carboplatin/
toposide within 3 months, and this suggests the fea-
ibility of incorporating our regimen into a strategy of
equential cycles of non–cross-resistant HDC. Addi-
ionally, it could be combined with molecularly tar-
eted therapeutics, building on the synergy between
ocetaxel and agents that target growth factor signal-
ng [9,66] or angiogenesis pathways [67].
In summary, a major 4-fold dose escalation of
ocetaxel is feasible combined with high-dose mel-
halan and carboplatin with AHPC support. Further
nvestigation of this regimen in disease-speciﬁc phase
I studies is warranted.
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